Apellis Pharmaceuticals Expands Leadership Team, Appoints Adam Townsend as Chief Commercial Officer
20 nov. 2018 07h00 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Reports Third Quarter 2018 Business Update and Financial Results
13 nov. 2018 08h00 HE
|
Apellis Pharmaceuticals, Inc.
- Commenced Phase 3 Program of APL-2 in Geographic Atrophy (GA) - - Cash Position of $220.6 Million at Quarter-End - CRESTWOOD, Ky. and CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Apellis...
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
07 nov. 2018 16h30 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Announces Poster Presentations at the American Society of Hematology Annual Meeting
01 nov. 2018 10h50 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
28 sept. 2018 09h00 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky., and WALTHAM Mass., Sept. 28, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Announces First Patient Dosed in Its Phase 3 Clinical Program for APL-2 in Patients With Geographic Atrophy
12 sept. 2018 07h30 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Announces that All Four Severely Anemic Soliris™-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria in Ongoing Phase 1b Trial Have Been Transitioned to APL-2 Monotherapy
04 sept. 2018 07h30 HE
|
Apellis Pharmaceuticals, Inc.
PHAROAH Trial Results to-Date Show APL-2 Monotherapy Eliminated Transfusion Dependency and Improved Markers of Anemia in PNH Patients on Soliris™ CRESTWOOD, Ky. and WALTHAM, Mass., Sept. 04, 2018 ...
Apellis Pharmaceuticals Reports Second Quarter 2018 Business Update and Financial Results
31 juil. 2018 16h30 HE
|
Apellis Pharmaceuticals, Inc.
- Commenced Phase 3 Trial of APL-2 in Paroxysmal Nocturnal Hemoglobinuria (PNH); APL-2 in Geographic Atrophy (GA) Remains On Track to Advance into Phase 3 in 2H18 - - Cash Position of $253.8 Million...
Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from FDA for the Treatment of Patients with Geographic Atrophy
24 juil. 2018 09h00 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky., and WALTHAM, Mass., July 24, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Announces First Patient Enrolled in Phase 3 APL-2 Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Soliris™
26 juin 2018 17h00 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky., and WALTHAM Mass., June 26, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...